

Martin KÅ¥berg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/786365/publications.pdf>

Version: 2024-02-01

21
papers

575
citations

840728

11
h-index

752679

20
g-index

21
all docs

21
docs citations

21
times ranked

991
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 125-133. | 8.1 | 128 |
| 2 | Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018, 68, 402-411. | 3.7 | 105 |
| 3 | Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. <i>Lancet Public Health</i> , The, 2021, 6, e309-e323. | 10.0 | 99 |
| 4 | The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 233-244. | 1.5 | 33 |
| 5 | Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program. <i>Infectious Diseases</i> , 2017, 49, 728-736. | 2.8 | 30 |
| 6 | Incidence and spontaneous clearance of hepatitis C virus (<scp>HCV</scp>) in people who inject drugs at the Stockholm Needle Exchangeâ€”Importance for <scp>HCV</scp> elimination. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1452-1461. | 2.0 | 30 |
| 7 | Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and gender. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 679-684. | 1.5 | 28 |
| 8 | Significant decrease in injection risk behaviours among participants in a needle exchange programme. <i>Infectious Diseases</i> , 2020, 52, 336-346. | 2.8 | 27 |
| 9 | Health literacy and changes in pattern of drug use among participants at the Stockholm Needle Exchange Program during the COVID-19 pandemic. <i>Harm Reduction Journal</i> , 2021, 18, 52. | 3.2 | 25 |
| 10 | A qualitative study of facilitators and barriers to participate in a needle exchange program for women who inject drugs. <i>Harm Reduction Journal</i> , 2020, 17, 84. | 3.2 | 21 |
| 11 | Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 727-734. | 1.5 | 15 |
| 12 | Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVIDâ€19. <i>Liver International</i> , 2021, 41, 2024-2031. | 3.9 | 9 |
| 13 | Hepatitis C virus (HCV) related liver fibrosis in people who inject drugs (PWID) at the Stockholm Needle Exchange â€” evaluated with liver elasticity. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 319-327. | 1.5 | 6 |
| 14 | Hepatitis C elimination â€” Macroâ€elimination. <i>Liver International</i> , 2020, 40, 61-66. | 3.9 | 4 |
| 15 | A prospective cohort study of risk behaviours, retention and loss to follow-up over 5 years among women and men in a needle exchange program in Stockholm, Sweden. <i>International Journal of Drug Policy</i> , 2021, 90, 103059. | 3.3 | 4 |
| 16 | Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 â€” is the precautionary principle applicable?. <i>Eurosurveillance</i> , 2021, 26, . | 7.0 | 4 |
| 17 | Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. <i>PLoS ONE</i> , 2021, 16, e0253710. | 2.5 | 3 |
| 18 | Treatment of hepatitis C at the Stockholm needle syringe program - treatment success, reinfection rates and challenges for HCV elimination. <i>Journal of Hepatology</i> , 2020, 73, S354-S355. | 3.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | HCV treatment for people with recent drug use: time for new measures of success?. The Lancet Gastroenterology and Hepatology, 2018, 3, 731-732. | 8.1 | 1 |
| 20 | High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. Scandinavian Journal of Gastroenterology, 2020, 55, 574-580. | 1.5 | 1 |
| 21 | Absence of interferon-Î» 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection. Scandinavian Journal of Gastroenterology, 2021, 56, 855-861. | 1.5 | 0 |